334 related articles for article (PubMed ID: 25815420)
1. ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial.
Schatzberg AF; DeBattista C; Lazzeroni LC; Etkin A; Murphy GM; Williams LM
Am J Psychiatry; 2015 Aug; 172(8):751-9. PubMed ID: 25815420
[TBL] [Abstract][Full Text] [Related]
2. Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial.
Arnow BA; Blasey C; Williams LM; Palmer DM; Rekshan W; Schatzberg AF; Etkin A; Kulkarni J; Luther JF; Rush AJ
Am J Psychiatry; 2015 Aug; 172(8):743-50. PubMed ID: 25815419
[TBL] [Abstract][Full Text] [Related]
3. Frontoparietal Activation During Response Inhibition Predicts Remission to Antidepressants in Patients With Major Depression.
Gyurak A; Patenaude B; Korgaonkar MS; Grieve SM; Williams LM; Etkin A
Biol Psychiatry; 2016 Feb; 79(4):274-81. PubMed ID: 25891220
[TBL] [Abstract][Full Text] [Related]
4. A cognitive-emotional biomarker for predicting remission with antidepressant medications: a report from the iSPOT-D trial.
Etkin A; Patenaude B; Song YJ; Usherwood T; Rekshan W; Schatzberg AF; Rush AJ; Williams LM
Neuropsychopharmacology; 2015 May; 40(6):1332-42. PubMed ID: 25547711
[TBL] [Abstract][Full Text] [Related]
5. Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein.
O'Connell CP; Goldstein-Piekarski AN; Nemeroff CB; Schatzberg AF; Debattista C; Carrillo-Roa T; Binder EB; Dunlop BW; Craighead WE; Mayberg HS; Williams LM
Am J Psychiatry; 2018 Mar; 175(3):251-261. PubMed ID: 29241359
[TBL] [Abstract][Full Text] [Related]
6. The international Study to Predict Optimized Treatment in Depression (iSPOT-D): outcomes from the acute phase of antidepressant treatment.
Saveanu R; Etkin A; Duchemin AM; Goldstein-Piekarski A; Gyurak A; Debattista C; Schatzberg AF; Sood S; Day CV; Palmer DM; Rekshan WR; Gordon E; Rush AJ; Williams LM
J Psychiatr Res; 2015 Feb; 61():1-12. PubMed ID: 25586212
[TBL] [Abstract][Full Text] [Related]
7. International Study to Predict Optimized Treatment for Depression (iSPOT-D), a randomized clinical trial: rationale and protocol.
Williams LM; Rush AJ; Koslow SH; Wisniewski SR; Cooper NJ; Nemeroff CB; Schatzberg AF; Gordon E
Trials; 2011 Jan; 12():4. PubMed ID: 21208417
[TBL] [Abstract][Full Text] [Related]
8. Association of ABCB1 gene variants, plasma antidepressant concentration, and treatment response: Results from a randomized clinical study.
Breitenstein B; Scheuer S; Brückl TM; Meyer J; Ising M; Uhr M; Holsboer F
J Psychiatr Res; 2016 Feb; 73():86-95. PubMed ID: 26704739
[TBL] [Abstract][Full Text] [Related]
9. Selecting among second-step antidepressant medication monotherapies: predictive value of clinical, demographic, or first-step treatment features.
Rush AJ; Wisniewski SR; Warden D; Luther JF; Davis LL; Fava M; Nierenberg AA; Trivedi MH
Arch Gen Psychiatry; 2008 Aug; 65(8):870-80. PubMed ID: 18678792
[TBL] [Abstract][Full Text] [Related]
10. Utility of event-related potentials in predicting antidepressant treatment response: An iSPOT-D report.
van Dinteren R; Arns M; Kenemans L; Jongsma ML; Kessels RP; Fitzgerald P; Fallahpour K; Debattista C; Gordon E; Williams LM
Eur Neuropsychopharmacol; 2015 Nov; 25(11):1981-90. PubMed ID: 26282359
[TBL] [Abstract][Full Text] [Related]
11. Effect of antidepressant treatment on cognitive impairments associated with depression: a randomised longitudinal study.
Shilyansky C; Williams LM; Gyurak A; Harris A; Usherwood T; Etkin A
Lancet Psychiatry; 2016 May; 3(5):425-35. PubMed ID: 26995298
[TBL] [Abstract][Full Text] [Related]
12. Amygdala Reactivity to Emotional Faces in the Prediction of General and Medication-Specific Responses to Antidepressant Treatment in the Randomized iSPOT-D Trial.
Williams LM; Korgaonkar MS; Song YC; Paton R; Eagles S; Goldstein-Piekarski A; Grieve SM; Harris AW; Usherwood T; Etkin A
Neuropsychopharmacology; 2015 Sep; 40(10):2398-408. PubMed ID: 25824424
[TBL] [Abstract][Full Text] [Related]
13. Brain imaging predictors and the international study to predict optimized treatment for depression: study protocol for a randomized controlled trial.
Grieve SM; Korgaonkar MS; Etkin A; Harris A; Koslow SH; Wisniewski S; Schatzberg AF; Nemeroff CB; Gordon E; Williams LM
Trials; 2013 Jul; 14():224. PubMed ID: 23866851
[TBL] [Abstract][Full Text] [Related]
14. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a second multicenter, randomized, double-blind, placebo-controlled study.
Marcus RN; McQuade RD; Carson WH; Hennicken D; Fava M; Simon JS; Trivedi MH; Thase ME; Berman RM
J Clin Psychopharmacol; 2008 Apr; 28(2):156-65. PubMed ID: 18344725
[TBL] [Abstract][Full Text] [Related]
15. Dimensions of anxiety in Major depressive disorder and their use in predicting antidepressant treatment outcome: an iSPOT-D report.
Braund TA; Palmer DM; Williams LM; Harris AWF
Psychol Med; 2020 Apr; 50(6):1032-1042. PubMed ID: 31023398
[TBL] [Abstract][Full Text] [Related]
16. Frontal and rostral anterior cingulate (rACC) theta EEG in depression: implications for treatment outcome?
Arns M; Etkin A; Hegerl U; Williams LM; DeBattista C; Palmer DM; Fitzgerald PB; Harris A; deBeuss R; Gordon E
Eur Neuropsychopharmacol; 2015 Aug; 25(8):1190-200. PubMed ID: 25936227
[TBL] [Abstract][Full Text] [Related]
17. Evaluation of a Machine Learning Model Based on Pretreatment Symptoms and Electroencephalographic Features to Predict Outcomes of Antidepressant Treatment in Adults With Depression: A Prespecified Secondary Analysis of a Randomized Clinical Trial.
Rajpurkar P; Yang J; Dass N; Vale V; Keller AS; Irvin J; Taylor Z; Basu S; Ng A; Williams LM
JAMA Netw Open; 2020 Jun; 3(6):e206653. PubMed ID: 32568399
[TBL] [Abstract][Full Text] [Related]
18. Effects of antidepressant medication on emotion regulation in depressed patients: an iSPOT-D report.
McRae K; Rekshan W; Williams LM; Cooper N; Gross JJ
J Affect Disord; 2014 Apr; 159():127-32. PubMed ID: 24679400
[TBL] [Abstract][Full Text] [Related]
19. Changes in BDNF serum levels in patients with major depression disorder (MDD) after 6 months treatment with sertraline, escitalopram, or venlafaxine.
Matrisciano F; Bonaccorso S; Ricciardi A; Scaccianoce S; Panaccione I; Wang L; Ruberto A; Tatarelli R; Nicoletti F; Girardi P; Shelton RC
J Psychiatr Res; 2009 Jan; 43(3):247-54. PubMed ID: 18511076
[TBL] [Abstract][Full Text] [Related]
20. ABCB1 (MDR1) predicts remission on P-gp substrates in chronic depression.
Ray A; Tennakoon L; Keller J; Sarginson JE; Ryan HS; Murphy GM; Lazzeroni LC; Trivedi MH; Kocsis JH; DeBattista C; Schatzberg AF
Pharmacogenomics J; 2015 Aug; 15(4):332-9. PubMed ID: 25487678
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
